Accupril patent litigation
Executive Summary
Trial in Pfizer's infringement case against Teva relating to the blood pressure agent Accupril (quinapril) will be limited to the validity of Pfizer's formulation patent claims and whether Warner-Lambert engaged in inequitable conduct in obtaining the patent. On Oct. 2, the court granted Pfizer's motion for summary judgment on infringement but rejected the company's motion for summary judgment on the validity of two patent claims...